Johnson & Johnson (JNJ) reported $23.74 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 5.8%. EPS of $2.77 for the same period compares to $2.82 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $22.8 billion, representing a surprise of +4.13%. The company delivered an EPS surprise of +4.14%, with the consensus EPS estimate being $2.66.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Johnson & Johnson performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Organic Sales Growth (Operational growth): 4.6% compared to the 2.7% average estimate based on four analysts.
- Sales- Innovative Medicine- Oncology- CARVYKTI- WW: $439 million compared to the $409.72 million average estimate based on four analysts. The reported number represents a change of +136% year over year.
- Sales- MedTech- Cardiovascular- ABIOMED- WW: $448 million versus the four-analyst average estimate of $423.95 million. The reported number represents a year-over-year change of +18.2%.
- Sales- MedTech- Cardiovascular- Other Cardiovascular- WW: $104 million versus the four-analyst average estimate of $98.4 million. The reported number represents a year-over-year change of +11.8%.
- Sales- Innovative Medicine- Neuroscience- SPRAVATO- WW: $414 million versus $371.85 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +52.8% change.
- Sales- MedTech- Total: $8.54 billion versus $8.25 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +7.3% change.
- Sales- Innovative Medicine- WW: $15.2 billion compared to the $14.55 billion average estimate based on six analysts. The reported number represents a change of +4.9% year over year.
- Sales- Innovative Medicine- Immunology- WW: $3.99 billion versus the five-analyst average estimate of $3.86 billion. The reported number represents a year-over-year change of -15.4%.
- Sales- Innovative Medicine- Neuroscience- WW: $2.05 billion versus $1.99 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +15.1% change.
- Sales- MedTech- Surgery- WW: $2.56 billion versus $2.49 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +2.7% change.
- Sales- Innovative Medicine- Oncology- WW: $6.31 billion versus the five-analyst average estimate of $6.04 billion. The reported number represents a year-over-year change of +24%.
- Sales- MedTech- Orthopaedics- WW: $2.31 billion versus $2.31 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -0.3% change.
View all Key Company Metrics for Johnson & Johnson here>>>
Shares of Johnson & Johnson have returned +1.8% over the past month versus the Zacks S&P 500 composite's +4.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
